...
机译:一项III期随机多中心试验,比较了伊立替康与北欧大剂量5-FU和亚叶酸方案或大剂量/注入的Gramont方案(Lv5FU2)联合治疗转移性结直肠癌患者的情况
Department of Oncology Radiology and Clinical Immunology Uppsala University Hospital Uppsala;
Department of Oncology and Pathology Karolinska Institutet Stockholm Sweden;
Department of Oncology Haukeland University Hospital Bergen;
Department of Oncology University Hospital Tromsö Norway;
Department of Oncology University Hospital Odense Denmark;
Department of Oncology Ullevål University Hospital Oslo;
Department of Hemato-Oncology Stavanger University Hospital Stavanger Norway;
Department of Oncology Central Hospital Herning Denmark;
Department of Oncology University Hospital Malmö;
Department of Oncology University Hospital Linköping;
Regional Oncologic Center Uppsala Sweden;
机译:一项随机III期多中心试验,比较了伊立替康与转移性结直肠癌患者的北欧快速推注5-FU和亚叶酸方案或推注/注入的格拉蒙特方案(Lv5FU2)。
机译:597 ORAL一项在转移性结直肠癌患者中比较伊立替康与北欧推注5FU和亚叶酸(5FU / FA)方案(FLIRI)或推注/灌输的de Gramont方案(FOLFIRI)的一项III期随机多中心试验。
机译:伊立替康与推注和大剂量5-FU和亚叶酸(改良的Gramont)输注用于晚期或转移性结直肠癌的一线或二线治疗的II期研究
机译:伊立替康与推注和大剂量5-FU和亚叶酸(改良的Gramont)输注用于晚期或转移性结直肠癌的一线或二线治疗的II期研究
机译:伊立替康大剂量推注5-FU和亚叶酸(改良的Gramont)II期研究用于晚期或转移性结直肠癌的一线或二线治疗